Revolutionizing Wound Care: NCB IT Hemostatic Pad Earns Insurance Approval, Paving the Way for Enhanced Patient Outcomes

[파이낸셜뉴스] The hemostasis pad for surgical operations, which NC&B subsidiary NCB IT focuses on, has been registered by the Health Insurance Review and Assessment Service.

According to NC&B on the 30th, NCBIT’s surgical hemostatic pad ‘STOPAD’ completed insurance registration with the Health Insurance Review and Assessment Service as a treatment material mid-class absorbable internal hemostatic product.

Star Pad is used to stop bleeding in internal tissue that occurs during surgical operations, and is a convergence medical product that combines medical devices and genetically recombinant hemostatic enzyme (rTLH).

When this product is applied to a bleeding area, it absorbs blood and causes red blood cells and platelets to aggregate. The genetically recombinant hemostatic enzyme cleaves fibrinogen and converts it to fibrin, forming a blood clot with the aggregated platelets. Through this, it induces hemostasis at the bleeding site in a short time.

StarPad proved its safety and effectiveness in domestic clinical trials compared to foreign hemostatic products registered as domestic drugs in 2020.

Previously, it obtained medical device product approval from the Ministry of Food and Drug Safety in December last year.

An NCBI IT official said, “It took a lot of time for StarPad, which was the first in the industry to incorporate genetically recombinant hemostatic enzymes, to be recognized as a treatment material for hemostasis,” and added, “We will now begin aggressive product marketing and generate full-scale sales starting next year.” .

He added, “This insurance registration will create an opportunity to improve and grow the level of domestic hemostatic products in the domestic medical market,” adding, “Following Star Pad, we plan to continue to introduce hemostatic products in various formulations such as sealants and powders.”

butter@fnnews.com Reporter Kang Kyung-rae

※ Copyright ⓒ Financial News, unauthorized reproduction and redistribution prohibited